Keybanc Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $440
Portfolio Pulse from richadhand@benzinga.com
Keybanc analyst Paul Knight maintains an Overweight rating on West Pharmaceutical Servs (NYSE:WST) and raises the price target from $415 to $440.
August 30, 2023 | 8:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
West Pharmaceutical Servs' price target has been raised from $415 to $440 by Keybanc, maintaining an Overweight rating.
The raised price target indicates the analyst's increased confidence in the company's performance. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100